Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$8.30 -2.2%	$12.10	$4.88 ▼ $19.58	$184.21M	N/A	68,683 shs	50,043 shs
ACIU AC Immune	$2.04 -0.5%	$2.13	$1.43 ▼ $3.98	$205.84M	1.65	109,799 shs	110,093 shs
CHUC Charlie's	$0.27 +3.2%	$0.13	$0.03 ▼ $0.28	$67.73M	0.95	370,051 shs	77,035 shs
CRGX CARGO Therapeutics	$4.47	$4.45	$3.00 ▼ $25.45	$216.17M	0.3	1.73 million shs	N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-5.56%	-12.74%	-34.59%	-19.30%	+848,999,900.00%
ACIU AC Immune	-0.97%	-2.38%	-12.77%	+18.23%	-34.71%
CHUC Charlie's	+0.58%	+29.05%	+171.68%	+137.01%	+134.64%
CRGX CARGO Therapeutics	0.00%	0.00%	-0.45%	+5.42%	-73.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACIU AC Immune	2.0507 of 5 stars	3.5	1.0	0.0	0.0	3.1	0.8	0.6
CHUC Charlie's	1.3351 of 5 stars	0.0	5.0	0.0	0.0	1.9	1.7	0.6
CRGX CARGO Therapeutics	2.0504 of 5 stars	2.9	0.0	0.0	0.0	2.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$32.60	292.77% Upside
ACIU AC Immune	3.00	Buy	$12.00	488.24% Upside
CHUC Charlie's	0.00	N/A	N/A	N/A
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	244.52% Upside

Current Analyst Ratings Breakdown

Latest CHUC, CRGX, AARD, and ACIU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $25.00
8/14/2025	AARD Aardvark Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $19.00
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
6/30/2025	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$6.31 per share	N/A
ACIU AC Immune	$31.02M	6.60	N/A	N/A	$0.90 per share	2.27
CHUC Charlie's	$8.49M	8.23	N/A	N/A	$0.01 per share	26.63
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$20.59M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ACIU AC Immune	-$57.83M	-$0.58	N/A	N/A	N/A	-174.94%	-49.35%	-23.16%	11/4/2025 (Estimated)
CHUC Charlie's	-$4.16M	$0.01	26.66	∞	N/A	19.36%	-174.49%	36.91%	11/17/2025 (Estimated)
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	11/11/2025 (Estimated)

Latest CHUC, CRGX, AARD, and ACIU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CHUC Charlie's	N/A	$0.02	N/A	$0.02	N/A	$2.54 million
8/13/2025	Q2 2025	AARD Aardvark Therapeutics	-$0.52	-$0.66	-$0.14	-$0.66	N/A	N/A
8/5/2025	Q2 2025	ACIU AC Immune	-$0.20	-$0.25	-$0.05	-$0.25	$1.98 million	$1.65 million
5/29/2025	Q4 2024	CHUC Charlie's	N/A	-$0.01	N/A	-$0.01	N/A	$1.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
CHUC Charlie's	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	14.04	14.04
ACIU AC Immune	N/A	1.33	1.33
CHUC Charlie's	0.07	1.61	0.61
CRGX CARGO Therapeutics	N/A	12.37	12.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ACIU AC Immune	51.36%
CHUC Charlie's	7.80%
CRGX CARGO Therapeutics	93.16%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
ACIU AC Immune	4.60%
CHUC Charlie's	20.90%
CRGX CARGO Therapeutics	2.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
ACIU AC Immune	140	100.41 million	95.79 million	Optionable
CHUC Charlie's	40	262.43 million	207.59 million	Not Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A

CHUC, CRGX, AARD, and ACIU Headlines

Recent News About These Companies

Wall Street Zen Upgrades CARGO Therapeutics (NASDAQ:CRGX) to Sell

August 25, 2025 | marketbeat.com

CARGO Therapeutics (NASDAQ:CRGX) Upgraded to Sell at Wall Street Zen

August 23, 2025 | americanbankingnews.com

CARGO Therapeutics Acquired by Concentra Biosciences

August 19, 2025 | tipranks.com

CARGO Therapeutics (CRGX) Expected to Announce Earnings on Monday

August 5, 2025 | marketbeat.com

Alberta Investment Management Corp Takes $380,000 Position in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

August 5, 2025 | marketbeat.com

TD Asset Management Inc Decreases Holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX)

August 5, 2025 | marketbeat.com

CARGO Therapeutics, Inc. (NASDAQ:CRGX) Given Average Rating of "Reduce" by Brokerages

August 3, 2025 | marketbeat.com

Monaco Asset Management SAM Buys Shares of 139,028 CARGO Therapeutics, Inc. (NASDAQ:CRGX)

July 31, 2025 | marketbeat.com

Jefferies Raises Price Target for Cargo Therapeutics (CRGX), Keeps Hold Rating

July 29, 2025 | msn.com

CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGX

July 25, 2025 | businesswire.com

URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger - CRGX, HSON, BRZH, and ENZB

July 25, 2025 | prnewswire.com

CRGX - Cargo Therapeutics Inc Financials | Morningstar

July 19, 2025 | morningstar.comM

CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of ...

July 11, 2025 | morningstar.comM

Concentra Biosciences Set to Acquire CAR T-Cell Innovator CARGO Therapeutics in Cash Deal

July 10, 2025 | hoodline.comH

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - Seeking Alpha

July 9, 2025 | seekingalpha.com

CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right - Morningstar

July 9, 2025 | morningstar.comM

CARGO Therapeutics to be acquired by Concentra Biosciences in $4.379 a - Seeking Alpha

July 9, 2025 | seekingalpha.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CARGO Therapeutics, Inc. (NASDAQ: CRGX)

July 9, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRGX and WNS on Behalf of Shareholders

July 9, 2025 | globenewswire.com

Concentra extends biotech shopping spree by collecting Cargo

July 8, 2025 | fiercebiotech.comF

Tang Capital makes bid for 4th Bay Area biotech in 3 months, offering to take out Cargo Therapeutics

July 8, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHUC, CRGX, AARD, and ACIU Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$8.30 -0.19 (-2.24%)

As of 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

AC Immune NASDAQ:ACIU

$2.04 -0.01 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.07 +0.03 (+1.47%)

As of 07:43 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Charlie's OTCMKTS:CHUC

$0.27 +0.01 (+3.18%)

As of 03:59 PM Eastern

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

CARGO Therapeutics NASDAQ:CRGX

$4.47 0.00 (0.00%)

As of 08/19/2025

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time